Effective Use of Autoantibody Tests in the Diagnosis of Systemic Autoimmune Disease

  title={Effective Use of Autoantibody Tests in the Diagnosis of Systemic Autoimmune Disease},
  author={Robert Lyons and Sonali Narain and Cody Nichols and Minoru Satoh and Westley H. Reeves},
  journal={Annals of the New York Academy of Sciences},
Abstract: Screening for disease‐specific autoantibodies may be useful in asymptomatic ANA‐positive individuals as a means of evaluating the risk of developing a systemic autoimmune disease such as systemic lupus erythematosus (SLE), polymyositis/dermatomyositis /PM/DM), scleroderma (SSc), Sjögren's syndrome (SS), rheumatoid arthritis (RA), or primary biliary cirrhosis (PBC) in the future. In patients with known or suspected systemic autoimmune disease, a panel of disease‐specific markers may… 

Autoantibody Determination in the Diagnosis of Systemic Lupus Erythematosus

While the American College of Rheumatology classification criteria for SLE are primarily a tool for research, they may be useful clinically, in that those patients fulfilling four or more criteria are highly likely to have SLE.

Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus

The sensitivity, specificity and diagnostic value of emerging biomarkers from recent studies are summarized, and the potential of these markers in the development of biomarker panel based diagnostics or disease monitoring system in SLE is discussed.

Interpreting serological tests in diagnosing autoimmune liver diseases.

Little prognostic value has been observed for any of the ALD serum hallmarks, and a vigorous effort to investigate new and old markers should therefore be undertaken in longitudinal studies as in the recent paradigm of PBC-specific antinuclear antibodies.

Autoantibodies in Wilson disease: Impact on clinical course

D‐penicillamine treatment was associated with a higher presence of ANA than zinc sulfate but without an increase in autoimmune diseases rate, and all studied autoantibodies was higher in WD patients in comparison to healthy subjects.

A Case of Primary Biliary Cirrhosis in Association with an Overlap Syndrome of Systemic Sclerosis and Systemic Lupus Erythematosus

A 52-year-old female admitted with fatigue and dyspnea was diagnosed as having SLE, as she satisfied the 4 relative diagnostic criteria-arthritis, AIHA, positive antinuclear antibody and positive antiphospholipid antibodies.

Advances in the diagnosis and classification of systemic lupus erythematosus

This review compares old and new classification criteria, discussing their application and pinpointing their limitations in the management of patients, and focuses on current and novel biomarkers for SLE diagnosis, highlighting their predictive value and applicability in clinical practice.

Libyan International Medical University Faculty of Basic Medical Science Mangment of Systemic Lupus Erythematous

Evidence supports the use of glucocorticoids alone or in combination with immunosuppressive therapy for SLE-related neuropsychiatric disease, and antiplatelet and/or anticoagulation therapy is recommended for NPSLE manifestations related to antiphospholipid antibodies.

Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes

The results revealed that all of these ENA-6 and Sm antibodies as biomarkers complement diagnoses of active SLE but their use as solo markers does not allow classifying patients with SLE.

Autoantibodies and Biomarkers: Diagnostic Aspects

An overview of the autoantibodies most commonly used in routine clinical practice is offered, as the particular assay used remarkably influences the interpretation of the test.



Clinical features and evolution of antinuclear antibody positive individuals in a rheumatology outpatient clinic.

ANA may connote a form of systemic autoimmunity that is expressed as a wide variety of complaints, even in the absence of a definite diagnosis of CTD.

Development of Anti‐dsDNA Autoantibodies Prior to Clinical Diagnosis of Systemic Lupus Erythematosus

The data suggest that anti‐dsDNA antibodies are present in SLE patient sera much earlier than previously suspected, and are consistent with increases in anti-dsDNA levels contributing to the onset of clinical illness in some patients with SLE.

Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

The onset and progression of autoantibody development before the clinical diagnosis of systemic lupus erythematosus is investigated, with a progressive accumulation of specificAutoantibodies before the onset of SLE, while patients are still asymptomatic.

Range of antinuclear antibodies in "healthy" individuals.

It is recommended that laboratories performing immunofluorescent ANA tests should report results at both the 1:40 and 1:160 dilutions, and should supply information on the percentage of normal individuals who are positive at these dilutions.

Strong association of autoantibodies to human nuclear lamin B1 with lupus anticoagulant antibodies in systemic lupus erythematosus.

High titers of IgG anti-lamin B1 autoantibodies are highly specific for a subset of SLE patients whose clinical characteristics include the presence of LAC and other laboratory manifestations of the antiphospholipid syndrome.

Correlation of antisynthetase antibody levels with disease course in a patient with interstitial lung disease and elevated muscle enzymes.

The results suggest that certain autoantibodies, such as antiglycyl tRNA synthetase, might reflect an underlying pathologic process (in this case, myositis and interstitial lung disease) irrespective of disease diagnosis, and that quantitative immunoprecipitation may be a useful technique for investigating the relationship between specificAutoantibody production and organ involvement in systemic autoimmune disease.

Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma.

Anti-PM/Scl may be a marker for atypical or subclinical presentations of the usually associated disease, or this autoantibody may precede expression of the underlying disease.

The diagnostic associations of patients with antinuclear antibodies referred to a community rheumatologist.

Undiagnosed autoimmune thyroid disease and SLE are common diagnostic associations of positive ANA in patients referred to a community rheumatologist andpositive ANA are frequently associated with clinical disease.

Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

Within the subset of diffuse scleroderma, anti-Scl-70 was associated with peripheral vascular disease (digital pitting scars) and pulmonary interstitial fibrosis, but was not predictive of cardiac or renal involvement or survival.

Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.

Testing for anti-CCP antibodies in UA allows accurate prediction of a substantial number of patients who will fulfill the ACR criteria for RA.